<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ESCITALOPRAM OXALATE  - escitalopram oxalate solution </strong><br>Camber Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use escitalopram oxalate safely and effectively. See full prescribing information for escitalopram oxalate<br><br>Escitalopram Oxalate Oral Solution <br>Initial U.S. Approval: 2002 <br>Rx only</span></div>
<div class="Warning"><div>
<br><span class="Bold">WARNING: Suicidality and Antidepressant Drugs<br><span class="Italics">See full prescribing information for complete boxed warning.</span><br>Increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Escitalopram oxalate is not approved for use in pediatric patients less than 12 years of age (<a href="#Section_5.1">5.1</a>).</span>
</div></div>
<div></div>
<div class="Warning"><div>
<br><span class="Bold">WARNING: Suicidality and Antidepressant Drugs<br><span class="Italics">See full prescribing information for complete boxed warning.</span><br>Increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Escitalopram oxalate is not approved for use in pediatric patients less than 12 years of age (<a href="#Section_5.1">5.1</a>).</span>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<br>Escitalopram oxalate oral solution is a selective serotonin reuptake inhibitor (SSRI) indicated for: <br>•   Acute and Maintenance Treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD) in adults and adolescents aged 12 to 17 years (<a href="#Section_1.1">1.1</a>) <br>•   Acute Treatment of <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span> (GAD) in  adults (<a href="#Section_1.2">1.2</a>)</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<br>Escitalopram oxalate oral solution should generally be administered once daily, morning or evening with or without food (<a href="#Section_2.1">2.1</a>, <a href="#Section_2.4">2.2</a>).<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<br>Indication</td>
<td class="Rrule" valign="top">Recommended Dose</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">MDD (<a href="#Section_2.1">2.1</a>)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Adolescents (<a href="#Section_2.1">2.1</a>)</td>
<td class="Rrule" valign="top">
<br>Initial: 10 mg once daily<br>Recommended: 10 mg once daily<br>Maximum: 20 mg once daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Adults (<a href="#Section_2.1">2.1</a>)</td>
<td class="Rrule" valign="top">Initial: 10 mg once daily<br>Recommended: 10 mg once daily            <br>Maximum: 20 mg once daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">GAD (<a href="#Section_2.4">2.2</a>)</td>
<td class="Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Adults (<a href="#Section_2.4">2.2</a>)</td>
<td class="Rrule" valign="top">Initial: 10 mg once daily<br>Recommended: 10 mg once daily</td>
</tr>
</tbody></table>
<br>• No additional benefits seen at 20 mg/day dose (<a href="#Section_2.1">2.1</a>).<br>• 10 mg/day is the recommended dose for most elderly patients and patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#Section_2.3">2.3</a>). <br>• No dosage adjustment for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Use caution in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#Section_2.3">2.3</a>). <br>• Discontinuing escitalopram oxalate oral solution: A gradual dose reduction is recommended (<a href="#Section_2.5">2.4</a>).</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<br>• Oral solution: 1 mg per mL (<a href="#Section_3.1">3.2</a>)</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<br>• Monoamine Oxidase Inhibitors: Do not use with an MAOI or within 14 days ofstopping an MAOI. Allow 14 days after stopping escitalopram oxalate before starting an MAOI (<a href="#Section_4.1">4.1</a>, <a href="#Section_5.11">5.10</a>).<br>• Pimozide: Do not use concomitantly (<a href="#Section_4.2">4.2</a>, <a href="#Section_7.11">7.10</a>). <br>• Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to escitalopram or citalopram or any   of the inactive ingredients (<a href="#Section_4.3">4.3</a>).</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<br>• Clinical Worsening/<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk: Monitor for clinical worsening, suicidality and unusual change in behavior, especially, during the initial few months of therapy or at times of dose changes (<a href="#Section_5.1">5.1</a>). <br>• <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-like Reactions: Manage with immediate discontinuation and continuing monitoring (<a href="#Section_5.2">5.2</a>). <br>• Discontinuation of Treatment with Escitalopram oxalate: A gradual reduction in dose rather than abrupt cessation is   recommended whenever possible (<a href="#Section_5.4">5.3</a>). <br>• <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: Prescribe with care in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (<a href="#Section_5.5">5.4</a>). <br>• Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span>: Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (<a href="#Section_5.6">5.5</a>). <br>• <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>: Can occur in association with <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span> (<a href="#Section_5.7">5.6</a>). <br>• Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>: Use caution in concomitant use with   NSAIDs, aspirin, warfarin or other drugs that affect coagulation (<a href="#Section_5.8">5.7</a>). <br>• Interference with Cognitive and Motor Performance: Use caution when operating machinery (<a href="#Section_5.9">5.8</a>). <br>• Use in Patients with Concomitant Illness: Use caution in patients with diseases or conditions that produce altered metabolism or hemodynamic responses (<a href="#Section_5.10">5.9</a>).</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<br>Most commonly observed adverse reactions (incidence ≥ 5% and at least twice the incidence of placebo patients) are: <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span> (primarily ejaculatory delay), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, decreased libido, and <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span> (<a href="#Section_6.1">6.1</a>). <br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Hetero Labs Limited at 866-495-1995, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<br>Concomitant use with SSRIs, SNRIs or Tryptophan is not recommended (<a href="#Section_7.1">7.1</a>). <br>Use caution when concomitant use with drugs that affect Hemostasis (NSAIDs, Aspirin, Warfarin) (<a href="#Section_7.7">7.6</a>).</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<br>Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus (<a href="#Section_8.1">8.1</a>).<br>Nursing Mothers: Caution should be exercised when administered to a nursing woman (<a href="#Section_8.3">8.3</a>)<br>Pediatric Use: Safety and effectiveness of escitalopram oxalate has not been established in pediatric MDD patients less than 12 years of age (<a href="#Section_8.4">8.4</a>).</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 10/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: Suicidality and Antidepressant Drugs</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS &amp; USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE &amp; ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Special Populations</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Discontinuation of Treatment with Escitalopram oxalate oral solution</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Switching Patients To or From a Monoamine Oxidase Inhibitor</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS &amp; STRENGTHS</a></h1>
<h2><a href="#section-3.1" class="toc">3.2 Oral Solution</a></h2>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Monoamine oxidase inhibitors (MAOIs)</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Pimozide</a></h2>
<h2><a href="#section-4.3" class="toc">4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to escitalopram or citalopram</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or Neuroleptec Malignant Syndrome (NMS)-likeReactions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Discontinuation of Treatment with Escitalopram oxalate</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Interference with Cognitive and Motor Performance</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Use in Patients with Concomitant </a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Potential for Interaction with Monoamine Oxidase Inhibitors</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Serotonergic Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Triptans</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 CNS Drugs</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Alcohol </a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Monoamine Oxidase Inhibitors (MAOIs) </a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Drugs that Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Cimetidine</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Digoxin</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Lithium</a></h2>
<h2><a href="#section-7.10" class="toc">7.10 Pimozide and Citalopram</a></h2>
<h2><a href="#section-7.11" class="toc">7.11 Sumatriptan</a></h2>
<h2><a href="#section-7.12" class="toc">7.12 Theophylline</a></h2>
<h2><a href="#section-7.13" class="toc">7.13 Warfarin</a></h2>
<h2><a href="#section-7.14" class="toc">7.14 Carbamazepine</a></h2>
<h2><a href="#section-7.15" class="toc">7.15 Triazolam</a></h2>
<h2><a href="#section-7.16" class="toc">7.16 Ketoconazole</a></h2>
<h2><a href="#section-7.17" class="toc">7.17 Ritonavir</a></h2>
<h2><a href="#section-7.18" class="toc">7.18 CYP3A4 and -2C19 Inhibitors</a></h2>
<h2><a href="#section-7.19" class="toc">7.19 Drugs Metabolized by Cytochrome P4502D6</a></h2>
<h2><a href="#section-7.20" class="toc">7.20 Metoprolol</a></h2>
<h2><a href="#section-7.21" class="toc">7.21 Electroconvulsive Therapy (ECT)</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor &amp; Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.2 Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Human Experience</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis &amp; Mutagenesis &amp; Impairment Of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Pharmacology &amp; OR Toxicology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.2 Oral Solution</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Information for Patients</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 FDA-Approved Medication Guide</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Section_0"></a><a name="section-1"></a><p></p>
<h1>WARNING: Suicidality and Antidepressant Drugs</h1>
<br><span class="Bold">WARNINGS: SUICIDALITY AND ANTIDEPRESSANT DRUGS<br>Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Anyone considering the use of escitalopram oxalate or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and certain other psychiatric disorders are themselves associated with increases in the risk of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Escitalopram oxalate is not approved for use in pediatric patients less than 12 years of age. <span class="Italics">[See <a href="#Section_5.1">Warnings and Precautions: Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk (5.1)</a>, <a href="#Section_17.1">Patient Counseling Information: Information for Patients (17.1)</a>, and <a href="#Section_8.4">Used in Specific Populations: Pediatric Use (8.4)</a>].</span></span>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS &amp; USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<br>Escitalopram oxalate oral solution is indicated for the acute and maintenance treatment of   major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> in adults and in adolescents 12 to 17 years of age [<span class="Italics">see <a href="#Section_14.1">Clinical Studies (14.1)</a></span>]. <br> <br>A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span>, loss of interest in usual activities, significant change in weight and/or appetite, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span> or retardation, increased <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, feelings of guilt or worthlessness, <span class="product-label-link" type="condition" conceptid="4111210" conceptname="Bradyphrenia">slowed thinking</span> or impaired concentration, a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></h2>
<br>Escitalopram oxalate oral solution is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span> (GAD) in adults [<span class="Italics">see <a href="#Section_14.2">Clinical Studies (14.2)</a></span>].<br> <br><span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span> (DSM-IV) is characterized by excessive <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following symptoms: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, muscle <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, and <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbance</span>.</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE &amp; ADMINISTRATION</h1>
<br>Escitalopram oxalate oral solution should be administered once daily, in the morning or evening, with or without food.<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<br><span class="Bold">Initial Treatment<br>Adolescents<br></span>The recommended dose of escitalopram oxalate oral solution is 10 mg once daily. A flexible-dose trial of escitalopram oxalate oral solution (10 to 20 mg/day) demonstrated the effectiveness of escitalopram oxalate oral solution [<span class="Italics">see <a href="#Section_14.1">Clinical Studies (14.1)</a></span>]. If the dose is increased to 20 mg, this should occur after a minimum of three weeks. <br><br><span class="Bold">Adults<br></span>The recommended dose of escitalopram oxalate oral solution is 10 mg once daily. A fixed-dose trial of escitalopram oxalate oral solution demonstrated the effectiveness of both 10 mg and 20 mg of escitalopram oxalate oral solution, but failed to demonstrate a greater benefit of 20 mg over 10 mg [<span class="Italics">see <a href="#Section_14.1">Clinical Studies (14.1)</a></span>]. If the dose is increased to 20 mg, this should occur after a minimum of one week.<br> <br><span class="Bold">Maintenance Treatment <br></span>It is generally agreed that acute episodes of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> require several months or longer of sustained pharmacological therapy beyond response to the acute episode. Systematic evaluation of continuing escitalopram oxalate oral solution 10 or 20 mg/day in adults patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> who responded while taking escitalopram oxalate oral solution during an 8-week, acute-treatment phase demonstrated a benefit of such maintenance treatment [<span class="Italics">see <a href="#Section_14.1">Clinical Studies (14.1)</a></span>]. Nevertheless, the physician who elects to use escitalopram oxalate oral solution for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Patients should be periodically reassessed to determine the need for maintenance treatment.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></h2>
<br><span class="Bold">Initial Treatment <br><br>Adults</span><br>The recommended starting dose of escitalopram oxalate oral solution is 10 mg once daily. If the dose is increased to 20 mg, this should occur after a minimum of one week. <br> <br><span class="Bold">Maintenance Treatment</span><br><span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized anxiety disorder</span> is recognized as a chronic condition. The efficacy of escitalopram oxalate oral solution in the treatment of GAD beyond 8 weeks has not been systematically studied. The physician who elects to use escitalopram oxalate oral solution for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Special Populations</h2>
<br>10 mg/day is the recommended dose for most elderly patients and patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <br>No dosage adjustment is necessary for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Escitalopram oxalate oral solution should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.5"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Discontinuation of Treatment with Escitalopram oxalate oral solution</h2>
<br>Symptoms associated with discontinuation of escitalopram oxalate oral solution and other SSRIs and SNRIs have been reported [<span class="Italics">see <a href="#Section_5.4">Warnings and Precautions (5.3)</a></span>]. Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.6"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Switching Patients To or From a Monoamine Oxidase Inhibitor</h2>
<br>At least 14 days should elapse between discontinuation of an MAOI and initiation of escitalopram oxalate oral solution therapy. Similarly, at least 14 days should be allowed after stopping escitalopram oxalate oral solution before starting an MAOI [<span class="Italics">see <a href="#Section_4.1">Contraindications (4.1)</a> and <a href="#Section_5.11">Warnings and Precautions (5.10)</a></span>].</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS &amp; STRENGTHS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_3.1"></a><a name="section-3.1"></a><p></p>
<h2>3.2 Oral Solution</h2>
<br>Escitalopram oxalate oral solution contains escitalopram oxalate equivalent to 1 mg/mL esitalopram base.</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Monoamine oxidase inhibitors (MAOIs)</h2>
<br>Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated [<span class="Italics"><span class="Italics">see<a href="#Section_5.11">Warnings and Precautions (5.10)</a>].</span></span>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Pimozide</h2>
<br>Concomitant use in patients taking pimozide is contraindicated [<span class="Italics">see <a href="#Section_7.11">Drug Interactions (7.10)</a></span>].</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to escitalopram or citalopram</h2>
<br>Escitalopram oxalate oral solution is contraindicated in patients with a hypersensitivity   to escitalopram or citalopram or any of the inactive ingredients in escitalopram oxalate oral solution.</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<br>Patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. <br> <br>The pooled analyses of placebo-controlled trials in children and adolescents with MDD, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 1<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="2" valign="top">TABLE 1<br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="Bold">Age Range</span></td>
<td class="Rrule" valign="top"><span class="Bold">Drug-Placebo Difference in Number of Cases of Suicidability per 1000 patients Treated</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"></td>
<td class="Rrule" valign="top">
<br>Increases Compared to Placebo</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&lt;18<br>
</td>
<td class="Rrule" align="center" valign="top">14 additional cases<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">18-24<br>
</td>
<td class="Rrule" align="center" valign="top">5 additional cases<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"></td>
<td class="Rrule" align="center" valign="top">Decreases Compared to Placebo<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">25-64<br>
</td>
<td class="Rrule" align="center" valign="top">1 fewer case<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">
<br>≥65</td>
<td class="Rrule" valign="top">
<br>6 fewer case</td>
</tr>
</tbody></table>
<br>No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric trials. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.<br><br>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. <br><br>All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. <br><br>The following symptoms, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, have been reported in adult and pediatric patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. <br><br>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. <br><br>If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [<span class="Italics">see <a href="#Section_2.5">Dosage and Administration (2.4)</a></span>]. <br><br>Families and caregivers of patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers [<span class="Italics">see also <a href="#Section_17.1">Patient Counseling Information (17.1)</a></span>]. Prescriptions for escitalopram oxalate should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.<br> <br><span class="Bold">Screening Patients for Bipolar Disorder</span><br>A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It should be noted that escitalopram oxalate is not approved for use in treating <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span>.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or Neuroleptec Malignant Syndrome (NMS)-likeReactions</h2>
<br>The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including escitalopram oxalate treatment, but particularly with concomitant use of serotonergic drugs (including triptans) with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>, in its most severe form can resemble <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, which includes <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuation of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>. Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or NMS-like signs and symptoms.<br><br>The concomitant use of escitalopram oxalate with MAOIs intended to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is contraindicated. If concomitant treatment of escitalopram oxalate with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.<br> <br>The concomitant use of escitalopram oxalate with serotonin precursors (such as tryptophan) is not recommended. Treatment with escitalopram oxalate and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Discontinuation of Treatment with Escitalopram oxalate</h2>
<br>During marketing of escitalopram oxalate and other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">electric shock sensations</span>), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms.<br> <br>Patients should be monitored for these symptoms when discontinuing treatment with escitalopram oxalate. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate [<span class="Italics">see <a href="#Section_2.5">Dosage and Administration (2.4)</a></span>].</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<br>Although anticonvulsant effects of racemic citalopram have been observed in animal studies, escitalopram oxalate has not been systematically evaluated in patients with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder. These patients were excluded from clinical studies during the product's premarketing testing. In clinical trials of escitalopram oxalate, cases of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span> have been reported in association with escitalopram oxalate treatment. Like other drugs effective in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>, escitalopram oxalate should be introduced with care in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></h2>
<br>In placebo-controlled trials of escitalopram oxalate in major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>, activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> was reported in one (0.1%) of 715 patients treated with escitalopram oxalate and in none of the 592 patients treated with placebo. One additional case of <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> has been reported in association with escitalopram oxalate treatment. Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> has also been reported in a small proportion of patients with major <span class="product-label-link" type="condition" conceptid="444100" conceptname="Mood disorder">affective disorders</span> treated with racemic citalopram and other marketed drugs effective in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>. As with all drugs effective in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>, escitalopram oxalate should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<br><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> may occur as a result of treatment with SSRIs and SNRIs, including escitalopram oxalate. In many cases, this <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> appears to be the result of the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>), and was reversible when escitalopram oxalate was discontinued. Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [<span class="Italics">see <a href="#Section_8.5">Geriatric Use (8.5)</a></span>]. Discontinuation of escitalopram oxalate should be considered in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and appropriate medical intervention should be instituted. <br><br>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which may lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. Signs and symptoms associated with more severe and/or acute cases have included <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.8"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<br>SSRIs and SNRIs, including escitalopram oxalate, may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to the risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events related to SSRIs and SNRIs use have ranged from <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> to life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>. <br><br>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of escitalopram oxalate and NSAIDs, aspirin, or other drugs that affect coagulation.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.9"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Interference with Cognitive and Motor Performance</h2>
<br>In a study in normal volunteers, escitalopram oxalate 10 mg/day did not produce impairment of intellectual function or psychomotor performance. Because any psychoactive drug may impair judgment, thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that escitalopram oxalate therapy does not affect their ability to engage in such activities.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.10"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Use in Patients with Concomitant </h2>
<br>Clinical experience with escitalopram oxalate in patients with certain concomitant systemic illnesses is limited. Caution is advisable in using escitalopram oxalate in patients with diseases or conditions that produce altered metabolism or hemodynamic responses.<br> <br>Escitalopram oxalate has not been systematically evaluated in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease. Patients with these diagnoses were generally excluded from clinical studies during the product's premarketing testing.<br><br>In subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, clearance of racemic citalopram was decreased and plasma concentrations were increased. The recommended dose of escitalopram oxalate in hepatically impaired patients is 10 mg/day [<span class="Italics">see <a href="#Section_2.3">Dosage and Administration (2.3)</a></span>].<br> <br>Because escitalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. Until adequate numbers of patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> have been evaluated during chronic treatment with escitalopram oxalate, however, it should be used with caution in such patients [<span class="Italics">see <a href="#Section_2.3">Dosage and Administration (2.3)</a></span>].</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.11"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Potential for Interaction with Monoamine Oxidase Inhibitors</h2>
<br>In patients receiving serotonin reuptake inhibitor drugs in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal, reactions including <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuations of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> that include extreme <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> progressing to <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on an MAOI. Some cases presented with features resembling <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>. Furthermore, limited animal data on the effects of combined use of SSRIs and MAOIs suggest that these drugs may act synergistically to elevate blood pressure and evoke behavioral excitation. Therefore, it is recommended that escitalopram oxalate should not be used in combination with an MAOI, or within 14 days of discontinuing treatment with an MAOI. Similarly, at least 14 days should be allowed after stopping escitalopram oxalate before starting an MAOI. <br><br><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> has been reported in two patients who were concomitantly receiving linezolid, an antibiotic which is a reversible non-selective MAOI.</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<br>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.<br> <br><span class="Bold">Clinical Trial Data Sources </span><br><span class="Bold">Pediatrics (6 to 17 years)</span><br>Adverse events were collected in 576 pediatric patients (286 escitalopram oxalate, 290 placebo) with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> in double-blind placebo-controlled studies. Safety and effectiveness of escitalopram oxalate in pediatric patients less than 12 years of age has not been established. <br><br><span class="Bold">Adults</span><br>Adverse events information for escitalopram oxalate was collected from 715 patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> who were exposed to escitalopram and from 592 patients who were exposed to placebo in double-blind, placebo-controlled trials. An additional 284 patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> were newly exposed to escitalopram in open-label trials. The adverse event information for escitalopram oxalate in patients with GAD was collected from 429 patients exposed to escitalopram and from 427 patients exposed to placebo in double-blind, placebo-controlled trials. <br><br>Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, standard World Health Organization (WHO) terminology has been used to classify reported adverse events. <br><br>The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. <br><br><span class="Bold">Adverse Events Associated with Discontinuation of Treatment</span><br><span class="Bold">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorder</span><br>Pediatrics (6 to 17 years)</span><br>Adverse events were associated with discontinuation of 3.5% of 286 patients receiving escitalopram oxalate and 1% of 290 patients receiving placebo. The most common adverse event (incidence at least 1% for escitalopram oxalate and greater than placebo) associated with discontinuation was <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (1% escitalopram oxalate, 0% placebo). <br><br><span class="Bold">Adults<br></span>Among the 715 depressed patients who received escitalopram oxalate in placebo-controlled trials, 6% discontinued treatment due to an adverse event, as compared to 2% of 592 patients receiving placebo. In two fixed-dose studies, the rate of discontinuation for adverse events in patients receiving 10 mg/day escitalopram oxalate was not significantly different from the rate of discontinuation for adverse events in patients receiving placebo. The rate of discontinuation for adverse events in patients assigned to a fixed dose of 20 mg/day escitalopram oxalate was 10%, which was significantly different from the rate of discontinuation for adverse events in patients receiving 10 mg/day escitalopram oxalate (4%) and placebo (3%). Adverse events that were associated with the discontinuation of at least 1% of patients treated with escitalopram oxalate, and for which the rate was at least twice that of placebo, were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2%) and <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span> (2% of male patients).<br><br><span class="Bold"><br><span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span><br>Adults<br></span>Among the 429 GAD patients who received escitalopram oxalate 10 to 20 mg/day in placebo-controlled trials, 8% discontinued treatment due to an adverse event, as compared to 4% of 427 patients receiving placebo. Adverse events that were associated with the discontinuation of at least 1% of patients treated with escitalopram oxalate, and for which the rate was at least twice the placebo rate, were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (1%), and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (1%).<br> <br><span class="Bold">Incidence of Adverse Reactions in Placebo-Controlled Clinical Trials<br>Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorder</span></span><br><span class="Bold">Pediatrics (6 to 17 years)<br></span>The overall profile of adverse reactions in pediatric patients was generally similar to that seen in adult studies, as shown in Table 2. However, the following adverse reactions (excluding those which appear in Table 2 and those for which the coded terms were uninformative or misleading) were reported at an incidence of at least 2% for escitalopram oxalate and greater than placebo: <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>.<br><br><span class="Bold">Adults<br></span>The most commonly observed adverse reactions in escitalopram oxalate patients (incidence of approximately 5% or greater and approximately twice the incidence in placebo patients) were <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span> (primarily ejaculatory delay), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.<br> <br>Table 2 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred among 715 depressed patients who received escitalopram oxalate at doses ranging from 10 to 20 mg/day in placebo-controlled trials. Events included are those occurring in 2% or more of patients treated with escitalopram oxalate and for which the incidence in patients treated with escitalopram oxalate was greater than the incidence in placebo-treated patients.<br>  <br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="3" valign="top">
<span class="Bold">TABLE 2</span><br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3" valign="top">
<span class="Bold">Treatment-Emergent Adverse Reactions observed with a frequency of ≥ 2% and greater than placebo for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="Underline"> Adverse Reaction</span></span><span class="Underline"></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold"><span class="Underline">Escitalopram oxalate</span></span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">         <span class="Underline">Placebo</span></span><span class="Underline"></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"> </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">(N=715)</span><br><span class="Bold">%</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">       (N=592) </span><br><span class="Bold">%</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Autonomic <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold"> </span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold"> </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span><br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating Increased</span><br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">
<span class="Bold">Central &amp; Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td class="Rrule" align="center" valign="top">15%<br>
</td>
<td class="Rrule" align="center" valign="top">7%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Indigestion</span><br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span><br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">General </span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like Symptoms<br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
<td class="Rrule" align="center" valign="top">4%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Psychiatric Disorders</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><br>
</td>
<td class="Rrule" align="center" valign="top">9%<br>
</td>
<td class="Rrule" align="center" valign="top">4%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Apetite Decreased<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span><br>
</td>
<td class="Rrule" align="center" valign="top">                 3%                       <br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span><br>
</td>
<td class="Rrule" valign="top">
<br>                5%                     </td>
<td class="Rrule" align="center" valign="top">4%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Sinustis<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Urogenital</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"> </span><span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Ejaculation Disorder</span><span class="Sup">1,2</span><br>
</td>
<td class="Rrule" align="center" valign="top">9%<br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span><span class="Sup">2</span><br>
</td>
<td class="Rrule" align="center" valign="top">                3%                       <br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1%<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">Anorgasmia</span><span class="Sup">3</span><br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1%<br>
</td>
</tr>
</tbody></table>
<br><span class="Sup">1</span> Primarily ejaculatory delay.<br><span class="Sup">2</span> Denominator used was for males only (N=225 Escitalopram oxalate; N=188 placebo).<br><span class="Sup">3</span> Denominator used was for females only (N=490 Escitalopram oxalate3; N=404 placebo).<br> <br><span class="Bold"><span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span> <br>Adults</span><br>The most commonly observed adverse reactions in escitalopram oxalate patients (incidence of approximately 5% or greater and approximately twice the incidence in placebo patients) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span> (primarily ejaculatory delay), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, decreased libido, and <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>.<br><br><span class="Bold">Table 3</span> enumerates the incidence, rounded to the nearest percent of treatment-emergent adverse events that occurred among 429 GAD patients who received escitalopram oxalate 10 to 20 mg/day in placebo-controlled trials. Events included are those occurring in 2% or more of patients treated with escitalopram oxalate and for which the incidence in patients treated with escitalopram oxalate was greater than the incidence in placebo-treated patients.<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="4" valign="top">
<span class="Bold">TABLE 3</span><br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4" valign="top">
<span class="Bold">Treatment-Emergent Adverse Reactions observed with a frequency of ≥ 2% and greater than placebo for <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">  <span class="Underline">Adverse Reactions</span></span><span class="Underline"></span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold"><span class="Underline">Escitalopram</span></span><span class="Bold"><span class="Underline">oxalate</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold"><span class="Underline">Placebo</span></span><span class="Underline"></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  <br>
</td>
<td class="Rrule" colspan="2" valign="top">  <br>
</td>
<td class="Rrule" valign="top">  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">  </span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">(N=429)</span><br><span class="Bold">%</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">(N=427)</span><br><span class="Bold">%</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">  Autonomic <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">  </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">  </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">9%<br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating Increased</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">4%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="4" valign="top">
<span class="Bold">  Central &amp; Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">24%<br>
</td>
<td class="Rrule" align="center" valign="top">17%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">2%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">  <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">  <br>
</td>
<td class="Rrule" align="center" valign="top">  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">18%<br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">8%<br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">5%<br>
</td>
<td class="Rrule" align="center" valign="top">4%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Indigestion</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">2%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">2%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">Toothache</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">2%<br>
</td>
<td class="Rrule" align="center" valign="top">0%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   General </span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">  <br>
</td>
<td class="Rrule" align="center" valign="top">  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">8%<br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">         <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like Symptoms<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">5%<br>
</td>
<td class="Rrule" align="center" valign="top">4%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="Bold">Musculoskeletal System Disorder </span><br>
</td>
<td class="Rrule" colspan="2" valign="top">
<span class="Bold">  </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">  </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">          Neck/<span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Shoulder Pain</span><br>
</td>
<td class="Rrule" colspan="2" valign="top">                  3%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   <span class="Bold">Psychiatric Disorders </span><br>
</td>
<td class="Rrule" colspan="2" valign="top">  <br>
</td>
<td class="Rrule" align="center" valign="top">  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">          <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"> 13%<br>
</td>
<td class="Rrule" align="center" valign="top">7%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">          <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">12%<br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">          <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">7%<br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">          <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Dreaming Abnormal</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">          <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite Decreased</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">          <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">  <br>
</td>
<td class="Rrule" align="center" valign="top">  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">          <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">Yawning</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">2%<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Urogenital              </span><br>
</td>
<td class="Rrule" align="center" valign="top">  <br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">           </span><span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Ejaculation Disorder</span><span class="Sup">1,2</span><br>
</td>
<td class="Rrule" align="center" valign="top">14%<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">2%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">           </span><span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">Anorgasmia</span><span class="Sup">3</span><br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">&lt;1%<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Bold">           </span>Menstrual Disorder  <br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">1%<br>
</td>
</tr>
</tbody></table>
<br><span class="Sup">1</span> Primarily ejaculatory delay.<br><span class="Sup">2</span> Denominator used was for males only (N=182 Escitalopram oxalate; N=195 placebo).<br><span class="Sup">3</span> Denominator used was for females only (N=247 Escitalopram oxalate3; N=232 placebo).<br> <br><span class="Bold">Dose Dependency of Adverse Reactions <br></span>The potential dose dependency of common adverse reactions (defined as an incidence rate of ≥5% in either the 10 mg or 20 mg escitalopram oxalate groups) was examined on the basis of the combined incidence of adverse reactions in two fixed-dose trials. The overall incidence rates of adverse events in 10 mg escitalopram oxalate-treated patients (66%) was similar to that of the placebo-treated patients (61%), while the incidence rate in 20 mg/day escitalopram oxalate-treated patients was greater (86%). Table 4 shows common adverse reactions that occurred in the 20 mg/day escitalopram oxalate group with an incidence that was approximately twice that of the 10 mg/day escitalopram oxalate group and approximately twice that of the placebo group.<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="4" valign="top">       <span class="Bold">TABLE 4 </span><br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4" valign="top">
<span class="Bold">Incidence of Common Adverse Reactions in Patients with </span><br><span class="Bold">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> </span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Adverse Reaction </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Placebo </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">10 mg/day </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">20 mg/day </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">  <br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">(N=311) </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Escitalopram </span><span class="Bold">oxalate</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Escitalopram</span><span class="Bold">oxalate</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">  </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">  </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">(N=310)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">(N=125)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">4% <br>
</td>
<td class="Rrule" align="center" valign="top">7% <br>
</td>
<td class="Rrule" align="center" valign="top">14% <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">5% <br>
</td>
<td class="Rrule" align="center" valign="top">6% <br>
</td>
<td class="Rrule" align="center" valign="top">14% <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span> </span><br>
</td>
<td class="Rrule" align="center" valign="top">3% <br>
</td>
<td class="Rrule" align="center" valign="top">4% <br>
</td>
<td class="Rrule" align="center" valign="top">9% <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </span><br>
</td>
<td class="Rrule" align="center" valign="top">1% <br>
</td>
<td class="Rrule" align="center" valign="top">4% <br>
</td>
<td class="Rrule" align="center" valign="top">9% <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">2% <br>
</td>
<td class="Rrule" align="center" valign="top">4% <br>
</td>
<td class="Rrule" align="center" valign="top">7% <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating Increased</span> </span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1% <br>
</td>
<td class="Rrule" align="center" valign="top">3% <br>
</td>
<td class="Rrule" align="center" valign="top">8% <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">1% <br>
</td>
<td class="Rrule" align="center" valign="top">3% <br>
</td>
<td class="Rrule" align="center" valign="top">6% <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">2% <br>
</td>
<td class="Rrule" align="center" valign="top">2% <br>
</td>
<td class="Rrule" align="center" valign="top">6% <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Indigestion</span> </span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">1% <br>
</td>
<td class="Rrule" align="center" valign="top">2% <br>
</td>
<td class="Rrule" align="center" valign="top">6% <br>
</td>
</tr>
</tbody></table>
<span class="Bold"><br><br>Male and Female <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">Sexual Dysfunction</span> with SSRIs</span><p class="First"><br>Although changes in sexual desire, sexual performance, and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that SSRIs can cause such untoward sexual experiences. </p>
<br> <br>Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling are likely to underestimate their actual incidence.<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="4" valign="top">
<br><span class="Bold">TABLE 5</span>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4" valign="top">
<br><span class="Bold">Incidence of Sexual Side Effects in Placebo-Controlled Clinical Trials</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" colspan="2" valign="top">
<br><span class="Bold">Adverse Event</span>
</td>
<td class="Rrule" valign="top">
<br><span class="Bold">Escitalopram</span><span class="Bold">oxalate</span>
</td>
<td class="Rrule" valign="top">
<br><span class="Bold">Placebo </span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br> </td>
<td class="Rrule" colspan="3" valign="top">
<br>In Males Only</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br> </td>
<td class="Rrule" colspan="2" valign="top">
<br>(N=407)</td>
<td class="Rrule" valign="top">
<br>(N=383)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">
<br><span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Ejaculation Disorder</span> (primarily ejaculatory delay) </td>
<td class="Rrule" valign="top">
<br>                 12% </td>
<td class="Rrule" valign="top">
<br>1% </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">
<br><span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span> </td>
<td class="Rrule" valign="top">
<br>                6% </td>
<td class="Rrule" valign="top">
<br>2% </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">
<br> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span> </td>
<td class="Rrule" valign="top">
<br>               2% </td>
<td class="Rrule" valign="top">
<br>&lt;1% </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br> </td>
<td class="Rrule" colspan="3" valign="top">
<br>In Females Only</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<br> </td>
<td class="Rrule" colspan="2" valign="top">
<br>(N=737)</td>
<td class="Rrule" valign="top">
<br>(N=636)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">
<br><span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span> </td>
<td class="Rrule" valign="top">
<br>              3% </td>
<td class="Rrule" valign="top">
<br>1% </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" colspan="2" valign="top">
<br><span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">Anorgasmia</span> </td>
<td class="Rrule" valign="top">
<br>            3% </td>
<td class="Rrule" valign="top">
<br>&lt;1% </td>
</tr>
</tbody></table>
<br><br>There are no adequately designed studies examining <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> with escitalopram oxalate treatment.<br><br><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> has been reported with all SSRIs. <br><br>While it is difficult to know the precise risk of <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.<br><br> <br><span class="Bold">Vital Sign Changes</span><br>Escitalopram oxalate and placebo groups were compared with respect to (1) mean change from baseline in vital signs (pulse, systolic blood pressure, and diastolic blood pressure) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses did not reveal any clinically important changes in vital signs associated with escitalopram oxalate treatment. In addition, a comparison of supine and standing vital sign measures in subjects receiving escitalopram oxalate indicated that escitalopram oxalate treatment is not associated with orthostatic changes.<br> <br><span class="Bold">Weight Changes</span><br>Patients treated with escitalopram oxalate in controlled trials did not differ from placebo-treated patients with regard to clinically important change in body weight. <br> <br><span class="Bold">Laboratory Changes</span><br>Escitalopram oxalate and placebo groups were compared with respect to (1) mean change from baseline in various serum chemistry, hematology, and urinalysis variables, and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in laboratory test parameters associated with escitalopram oxalate treatment. <br> <br><span class="Bold">ECG Changes</span><br>Electrocardiograms from escitalopram oxalate (N=625) and placebo (N=527) groups were compared with respect to outliers defined as subjects with QTc changes over 60 msec from baseline or absolute values over 500 msec post-dose, and subjects with heart rate increases to over 100 bpm or decreases to less than 50 bpm with a 25% change from baseline (tachycardic or bradycardic outliers, respectively). None of the patients in the escitalopram oxalate group had a QTcF interval &gt;500 msec or a prolongation &gt;60 msec compared to 0.2% of patients in the placebo group. The incidence of tachycardic outliers was 0.2% in the escitalopram oxalate and the placebo group. The incidence of bradycardic outliers was 0.5% in the escitalopram oxalate group and 0.2% in the placebo group. <br><br> <br>QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg) controlled cross-over, escalating multiple-dose study in 113 healthy subjects. The maximum mean (95% upper confidence bound) difference from placebo arm were 4.5 (6.4) and 10.7 (12.7) msec for 10 mg and supratherapeutic 30 mg escitalopram given once daily, respectively. Based on the established exposure-response relationship, the predicted QTcF change from placebo arm (95% confidence interval) under the Cmax for the dose of 20 mg is 6.6 (7.9) msec. Escitalopram 30 mg given once daily resulted in mean Cmax of 1.7-fold higher than the mean Cmax for the maximum recommended therapeutic dose at steady state (20 mg). The exposure under supratherapeutic 30 mg dose is similar to the steady state concentrations expected in CYP2C19 poor metabolizers following a therapeutic dose of 20 mg.<br><br><span class="Bold"><br>Other Reactions Observed During the Premarketing Evaluation of  Escitalopram oxalate</span><br>Following is a list of treatment-emergent adverse events, as defined in the introduction to the <span class="Bold">ADVERSE REACTIONS</span> section, reported by the 1428 patients treated with escitalopram oxalate for periods of up to one year in double-blind or open-label clinical trials during its premarketing evaluation. The listing does not include those events already listed in Tables 2 &amp; 3, those events for which a drug cause was remote and at a rate less than 1% or lower than placebo, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life threatening. Events are categorized by body system. Events of major clinical importance are described in the Warnings and Precautions section (5).<br> <br>Cardiovascular - <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>. <br><br> <br>Central and Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> - light-headed feeling, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. <br><br><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> - <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramp</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>. <br> <br>General - <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in limb</span>.<br> <br>Metabolic and Nutritional Disorders - increased weight.<br> <br>Musculoskeletal System Disorders - <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">jaw stiffness</span>.<br><br> <br>Psychiatric Disorders - appetite increased, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">concentration impaired</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>. <br><br> <br><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span> - <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span>, <span class="product-label-link" type="condition" conceptid="4172302" conceptname="Sinus headache">sinus headache</span>. <br><br> <br>Skin and Appendages Disorders - <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. <br><br>Special Senses - <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.<br><br>Urinary System Disorders - <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<br><span class="Bold">Adverse Reactions Reported Subsequent to the Marketing of Escitalopram <br></span>The following additional adverse reactions have been identified from spontaneous reports of escitalopram received worldwide. These adverse reactions have been chosen for inclusion because of a combination of seriousness, frequency of reporting, or potential causal connection to escitalopram and have not been listed elsewhere in labeling. However, because these adverse reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events include: <br><br>Blood and Lymphatic System Disorders: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, agranulocytis, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenia</span> purpura, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.<br> <br><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>. <br><br>Ear and labyrinth disorders: <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> <br><br><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span>: <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span>, <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>. <br><br><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>. <br><br><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorder</span>: <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>. <br><br>General Disorders and Administration Site Conditions: <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. <br><br>Hepatobiliary Disorders: fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>. <br><br><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.<br><br>Investigations: bilirubin increased, decreased weight, electrocardiogram QT prolongation,hepatic enzymes increased, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, INR increased, <br><span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> decreased. <br><br>Metabolism and Nutrition Disorders: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. <br><br>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>: <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramp</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle stiffness</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.<br><br><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4181630" conceptname="Choreoathetosis">choreoathetosis</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span>, <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizures</span> (or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>), <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoaesthesia</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">restless legs</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. <br><br>Pregnancy, Puerperium and Perinatal Conditions: <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>. <br><br>Psychiatric Disorders: acute <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression aggravated</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4233346" conceptname="Derealization">feeling unreal</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (visual and auditory), <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmare</span>, <span class="product-label-link" type="condition" conceptid="4196358" conceptname="Panic">panic reaction</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, self-harm or thoughts of self-harm, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal tendency</span>. <br><br>Renal and Urinary Disorders: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. <br><br>Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>: <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>. <br><br>Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn. <br><br>Skin and Subcutaneous Tissue Disorders: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. <br><br><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Serotonergic Drugs</h2>
<br>Based on the mechanism of action of SNRIs and SSRIs including escitalopram oxalate, and the potential for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, caution is advised when escitalopram oxalate is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort [<span class="Italics">see <a href="#Section_5.2">Warnings and Precautions (5.2)</a></span>]. The concomitant use of escitalopram oxalate with other SSRIs, SNRIs or tryptophan is not recommended.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Triptans</h2>
<br>There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with use of an SSRI and a triptan. If concomitant treatment of escitalopram oxalate with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [<span class="Italics">see <a href="#Section_5.2">Warnings and Precautions (5.2)</a></span>].</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.3"></a><p></p>
<h2>7.3 CNS Drugs</h2>
<br>Given the primary CNS effects of escitalopram, caution should be used when it is taken in combination with other centrally acting drugs.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.5"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Alcohol </h2>
<br>Although escitalopram oxalate did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking escitalopram oxalate is not recommended.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.6"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Monoamine Oxidase Inhibitors (MAOIs) </h2>
<br>[<span class="Italics">see <a href="#Section_4.1">Contraindications (4.1)</a> and <a href="#Section_5.11">Warnings and Precautions (5.10)</a></span>].</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.7"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Drugs that Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)</h2>
<br>Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> have also shown that concurrent use of an NSAID or aspirin may potentiate the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Altered anticoagulant effects, including increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, have been reported when SSRIs and SNRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when escitalopram oxalate is initiated or discontinued.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.8"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Cimetidine</h2>
<br>In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and C<span class="Sub">max</span> of 43% and 39%, respectively. The clinical significance of these findings is unknown.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.9"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Digoxin</h2>
<br>In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.10"></a><a name="section-7.9"></a><p></p>
<h2>7.9 Lithium</h2>
<br>Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when escitalopram oxalate and lithium are coadministered.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.11"></a><a name="section-7.10"></a><p></p>
<h2>7.10 Pimozide and Citalopram</h2>
<br>In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or C<span class="Sub">max</span> of pimozide. The mechanism of this <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> is not known.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.12"></a><a name="section-7.11"></a><p></p>
<h2>7.11 Sumatriptan</h2>
<p class="First">There have been rare postmarketing reports describing patients with <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span> following the use of an SSRI and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.13"></a><a name="section-7.12"></a><p></p>
<h2>7.12 Theophylline</h2>
<br>Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.14"></a><a name="section-7.13"></a><p></p>
<h2>7.13 Warfarin</h2>
<br>Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time was increased by 5%, the clinical significance of which is unknown.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.15"></a><a name="section-7.14"></a><p></p>
<h2>7.14 Carbamazepine</h2>
<br>Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.16"></a><a name="section-7.15"></a><p></p>
<h2>7.15 Triazolam</h2>
<br>Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.17"></a><a name="section-7.16"></a><p></p>
<h2>7.16 Ketoconazole</h2>
<br>Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg), a potent CYP3A4 inhibitor, decreased the C<span class="Sub">max</span> and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.19"></a><a name="section-7.17"></a><p></p>
<h2>7.17 Ritonavir</h2>
<br>Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.20"></a><a name="section-7.18"></a><p></p>
<h2>7.18 CYP3A4 and -2C19 Inhibitors</h2>
<br><span class="Italics">In vitro</span> studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.21"></a><a name="section-7.19"></a><p></p>
<h2>7.19 Drugs Metabolized by Cytochrome P4502D6</h2>
<br><span class="Italics">In vitro</span> studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited <span class="Italics">in vivo</span> data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in C<span class="Sub">max</span> and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.22"></a><a name="section-7.20"></a><p></p>
<h2>7.20 Metoprolol</h2>
<br>Administration of 20 mg/day escitalopram oxalate for 21 days in healthy volunteers resulted in a 50% increase in C<span class="Sub">max</span> and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg). Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of escitalopram oxalate and metoprolol had no clinically significant effects on blood pressure or heart rate.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.23"></a><a name="section-7.21"></a><p></p>
<h2>7.21 Electroconvulsive Therapy (ECT)</h2>
<br>There are no clinical studies of the combined use of ECT and escitalopram.</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<br><span class="Bold">Teratogenic Effects:</span><br>Pregnancy Category C <br>In a rat embryo/fetal development study, oral administration of escitalopram (56, 112, or 150 mg/kg/day) to pregnant animals during the period of organogenesis resulted in decreased fetal body weight and associated delays in ossification at the two higher doses (approximately ≥ 56 times the maximum recommended human dose [MRHD] of 20 mg/day on a body surface area [mg/m2] basis). Maternal toxicity (clinical signs and decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption), mild at 56 mg/kg/day, was present at all dose levels. The developmental no-effect dose of 56 mg/kg/day is approximately 28 times the MRHD on a mg/m2 basis. No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed at any of the doses tested (as high as 75 times the MRHD on a mg/m2 basis).<br> <br>         When female rats were treated with escitalopram (6, 12, 24, or 48 mg/kg/day) during pregnancy and through weaning, slightly increased offspring mortality and <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> were noted at 48 mg/kg/day which is approximately 24 times the MRHD on a mg/m2 basis. Slight maternal toxicity (clinical signs and decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) was seen at this dose. Slightly increased offspring mortality was also seen at 24 mg/kg/day. The no-effect dose was 12 mg/kg/day which is approximately 6 times the MRHD on a mg/m2 basis.       <br><br>         In animal reproduction studies, racemic citalopram has been shown to have adverse effects on embryo/fetal and postnatal development, including teratogenic effects, when administered at doses greater than human therapeutic doses.<br> <br><br>         In two rat embryo/fetal development studies, oral administration of racemic citalopram (32, 56, or 112 mg/kg/day) to pregnant animals during the period of organogenesis resulted in decreased embryo/fetal growth and survival and an increased incidence of fetal abnormalities (including cardiovascular and skeletal defects) at the high dose. This dose was also associated with maternal toxicity (clinical signs, decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>). The developmental no-effect dose was 56 mg/kg/day. In a rabbit study, no adverse effects on embryo/fetal development were observed at doses of racemic citalopram of up to 16 mg/kg/day. Thus, teratogenic effects of racemic citalopram were observed at a maternally toxic dose in the rat and were not observed in the rabbit.<br> <br>         When female rats were treated with racemic citalopram (4.8, 12.8, or 32 mg/kg/day) from late gestation through weaning, increased offspring mortality during the first 4 days after birth and persistent offspring <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> were observed at the highest dose. The no-effect dose was 12.8 mg/kg/day. Similar effects on offspring mortality and growth were seen when dams were treated throughout gestation and early lactation at doses ≥ 24 mg/kg/day. A no-effect dose was not determined in that study.<br> <br>There are no adequate and well-controlled studies in pregnant women; therefore, escitalopram should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. <br><br> <br>Pregnancy-Nonteratogenic Effects <br><br>         Neonates exposed to escitalopram oxalate and other SSRIs or SNRIs, late in the third trimester, have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temperature instability, feeding difficulty, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and constant <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> [<span class="Italics">see <a href="#Section_5.2">Warnings and Precautions (5.2)</a></span>].<br> <br><br>Infants exposed to SSRIs in late pregnancy may have an increased risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN). PPHN occurs in 1 to 2 per 1000 live births in the general population and is associated with substantial neonatal morbidity and mortality. In a retrospective, case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20th week of gestation compared to infants who had not been exposed to antidepressants during pregnancy. There is currently no corroborative evidence regarding the risk for PPHN following exposure to SSRIs in pregnancy; this is the first study that has investigated the potential risk. The study did not include enough cases with exposure to individual SSRIs to determine if all SSRIs posed similar levels of PPHN risk.<br> <br>When treating a pregnant woman with escitalopram oxalate during the third trimester, the physician should carefully consider both the potential risks and benefits of treatment [<span class="Italics">see <a href="#Section_2.1">Dosage and Administration (2.1)</a></span>]. Physicians should note that in a prospective longitudinal study of 201 women with a history of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> who were euthymic at the beginning of pregnancy, women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> than women who continued antidepressant medication.</div>
<div class="Section" data-sectionCode="34079-4">
<a name="Section_8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor &amp; Delivery</h2>
<br>The effect of escitalopram oxalate on labor and delivery in humans is unknown.</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<br>Escitalopram is excreted in human breast milk. Limited data from women taking 10 to 20 mg escitalopram showed that exclusively breast-fed infants receive approximately 3.9% of the maternal weight-adjusted dose of escitalopram and 1.7% of the maternal weight-adjusted dose of desmethylcitalopram. There were two reports of infants experiencing excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, decreased feeding, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in association with breastfeeding from a racemic citalopram-treated mother; in one case, the infant was reported to recover completely upon discontinuation of racemic citalopram by its mother and, in the second case, no follow-up information was available. Caution should be exercised and breastfeeding infants should be observed for adverse reactions when escitalopram oxalate is administered to a nursing woman.</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<br>         Safety and effectiveness of escitalopram oxalate has not been established in pediatric patients (less than 12 years of age) with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>. Safety and effectiveness of escitalopram oxalate has been established in adolescents (12 to 17 years of age) for the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> [see <a href="#Section_14.1">Clinical Studies (14.1)</a>]. Although maintenance efficacy in adolescent patients with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of escitalopram pharmacokinetic parameters in adults and adolescent patients. <br><br> <br>         Safety and effectiveness of escitalopram oxalate has not been established in pediatric patients less than 18 years of age with <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span>. <br><br> <br>         Decrease appetite and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> have been observed in association with the use of SSRIs. Consequently, regular monitoring of weight and growth should be performed in children and adolescents treated with an SSRI such as escitalopram oxalate.</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<br>Approximately 6% of the 1144 patients receiving escitalopram in controlled trials of escitalopram oxalate in major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> and GAD were 60 years of age or older; elderly patients in these trials received daily doses of escitalopram oxalate between 10 and 20 mg. The number of elderly patients in these trials was insufficient to adequately assess for possible differential efficacy and safety measures on the basis of age. Nevertheless, greater sensitivity of some elderly individuals to effects of escitalopram oxalate cannot be ruled out. <br><br>SSRIs and SNRIs, including escitalopram oxalate, have been associated with cases of clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in elderly patients, who may be at greater risk for this adverse event [<span class="Italics">see <a href="#Section_5.7"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> (5.6)</a></span>]. <br><br>In two pharmacokinetic studies, escitalopram half-life was increased by approximately 50% in elderly subjects as compared to young subjects and Cmax was unchanged [<span class="Italics">see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a></span>]. 10 mg/day is the recommended dose for elderly patients [<span class="Italics">see <a href="#Section_2.3">Dosage and Administration (2.3)</a></span>]. <br><br>Of 4422 patients in clinical studies of racemic citalopram, 1357 were 60 and over, 1034 were 65 and over, and 457 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but again, greater sensitivity of some elderly individuals cannot be ruled out.</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="Section_9"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_9.4"></a><a name="section-9.1"></a><p></p>
<h2>9.2 Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<br>Physical and Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> <br><br>Animal studies suggest that the abuse liability of racemic citalopram is low. Escitalopram oxalate has not been systematically studied in humans for its potential for abuse, tolerance, or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. The premarketing clinical experience with escitalopram oxalate did not reveal any drug-seeking behavior. However, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate escitalopram oxalate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse (e.g., development of tolerance, incrementations of dose, drug-seeking behavior).</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.1"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Human Experience</h2>
<br>In clinical trials of escitalopram, there were reports of escitalopram <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, including <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of up to 600 mg, with no associated fatalities. During the postmarketing evaluation of escitalopram, escitalopram oxalate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> involving <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of over 1000 mg have been reported. As with other SSRIs, a fatal outcome in a patient who has taken an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of escitalopram has been rarely reported. <br><br>Symptoms most often accompanying escitalopram <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, alone or in combination with other drugs and/or alcohol, included <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and ECG changes (including QT prolongation and very rare cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>). <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> has been very rarely reported accompanying <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.2"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<br>Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of escitalopram, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for escitalopram oxalate. <br><br>In managing overdosage, consider the possibility of multiple-drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<br> Escitalopram oxalate is an orally administered selective serotonin reuptake inhibitor (SSRI). Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+)-1-[3-(dimethyl-amino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate with the following structural formula: <br><br><div class="Figure"><img alt="structure.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=82d793ee-4039-45fc-ac83-4bd5235f00aa&amp;name=structure.jpg"></div>
<br> <br>The molecular formula is C20H21FN2O • C2H2O4 and the molecular weight is 414.40. <br><br>Escitalopram oxalate occurs as a fine, white to slightly-yellow powder and is freely soluble in methanol and dimethyl sulfoxide (DMSO), soluble in isotonic saline solution, sparingly soluble in water and ethanol, slightly soluble in ethyl acetate, and insoluble in heptane. <br><br>Escitalopram oxalate is available as an oral solution. <br><br>Escitalopram oxalate oral solution contains escitalopram oxalate equivalent to 1 mg/mL escitalopram base. It also contains the following inactive ingredients: anhydrous citric acid, glycerin, malic acid, methylparaben, natural peppermint flavor, non-crystallizing sorbital solution, propylene glycol, propylparaben, purified water and sodium citrate dihydrate.</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<br>The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<br><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies in animals suggest that escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine neuronal reuptake. Escitalopram is at least 100-fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake and inhibition of 5-HT neuronal firing rate. Tolerance to a model of antidepressant effect in rats was not induced by long-term (up to 5 weeks) treatment with escitalopram. Escitalopram has no or very low affinity for serotonergic (5-HT1 to 7) or other receptors including alpha- and beta-adrenergic, dopamine (D1 to 5), histamine (H1 to 3), muscarinic (M1 to 5), and benzodiazepine receptors. Escitalopram also does not bind to, or has low affinity for, various ion channels including Na+, K+, Cl-, and Ca++ channels. Antagonism of muscarinic, histaminergic, and adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular side effects of other psychotropic drugs.</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">         The single- and multiple-dose pharmacokinetics of escitalopram are linear and dose-proportional in a dose range of 10 to 30 mg/day. Biotransformation of escitalopram is mainly hepatic, with a mean terminal half-life of about 27 to 32 hours. With once-daily dosing, steady state plasma concentrations are achieved within approximately one week. At steady state, the extent of accumulation of escitalopram in plasma in young healthy subjects was 2.2 to 2.5 times the plasma concentrations observed after a single dose. The tablet and the oral solution dosage forms of escitalopram oxalate are bioequivalent. </p>
<p>         Absorption and Distribution </p>
<p>         Following a single oral dose (20 mg tablet or solution) of escitalopram, peak blood levels occur at about 5 hours. Absorption of escitalopram is not affected by food. </p>
<p>         The absolute bioavailability of citalopram is about 80% relative to an intravenous dose, and the volume of distribution of citalopram is about 12 L/kg. Data specific on escitalopram are unavailable. </p>
<p>         The binding of escitalopram to human plasma proteins is approximately 56%. </p>
<p> Metabolism and Elimination </p>
<p> Following oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance. </p>
<p>        Escitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT). In humans, unchanged escitalopram is the predominant compound in plasma. At steady state, the concentration of the escitalopram metabolite S-DCT in plasma is approximately one-third that of escitalopram. The level of S-DDCT was not detectable in most subjects. <span class="Italics">In vitro </span>studies show that escitalopram is at least 7 and 27 times more potent than S-DCT and S-DDCT, respectively, in the inhibition of serotonin reuptake, suggesting that the metabolites of escitalopram do not contribute significantly to the antidepressant actions of escitalopram. S-DCT and S-DDCT also have no or very low affinity for serotonergic (5-HT<span class="Sub">1 to 7</span>) or other receptors including alpha- and beta-adrenergic, dopamine (D<span class="Sub">1 to 5</span>), histamine (H<span class="Sub">1 to 3</span>), muscarinic (M<span class="Sub">1 to 5</span>), and benzodiazepine receptors. S-DCT and S-DDCT also do not bind to various ion channels including Na<span class="Sup">+</span>, K<span class="Sup">+</span>, Cl<span class="Sup">-</span>, and Ca<span class="Sup">++ </span>channels. </p>
<p><span class="Italics">               In vitro </span>studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of escitalopram. </p>
<p> Population Subgroups </p>
<p> <span class="Underline">Age </span></p>
<p>       Adolescents - In a single dose study of 10 mg escitalopram, AUC of escitalopram decreased by 19%, and C<span class="Sub">max</span> increased by 26% in healthy adolescent subjects (12 to 17 years of age) compared to adults. Following multiple dosing of 40 mg/day citalopram, escitalopram elimination half-life, steady-state C<span class="Sub">max</span> and AUC were similar in patients with MDD (12 to 17 years of age) compared to adult patients. No adjustment of dosage is needed in adolescent patients. </p>
<p>         Elderly - Escitalopram pharmacokinetics in subjects ≥ 65 years of age were compared to younger subjects in a single-dose and a multiple-dose study. Escitalopram AUC and half-life were increased by approximately 50% in elderly subjects, and C<span class="Sub">max </span>was unchanged. 10 mg is the recommended dose for elderly patients [<span class="Italics">see <a href="#Section_2.3">Dosage and Administration (2.3)</a></span>]. </p>
<p>         <span class="Underline">Gender</span> - Based on data from single- and multiple-dose studies measuring escitalopram in elderly, young adults, and adolescents, no dosage adjustment on the basis of gender is needed. </p>
<p>         <span class="Underline">Reduced hepatic function </span>- Citalopram oral clearance was reduced by 37% and half life was doubled in patients with reduced hepatic function compared to normal subjects. 10 mg is the recommended dose of escitalopram for most hepatically impaired patients [<span class="Italics">see <a href="#Section_2.3">Dosage and Administration (2.3)</a></span>]. </p>
<p>         <span class="Underline">Reduced renal function</span> - In patients with mild to moderate renal function impairment, oral clearance of citalopram was reduced by 17% compared to normal subjects. No adjustment of dosage for such patients is recommended. No information is available about the pharmacokinetics of escitalopram in patients with severely reduced renal function (creatinine clearance &lt; 20 mL/min). </p>
<p> <span class="Underline">Drug-Drug Interactions </span></p>
<br><span class="Italics">   In vitro </span>enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on <span class="Italics">in vitro </span>data, escitalopram would be expected to have little inhibitory effect on <span class="Italics">in vivo </span>metabolism mediated by these cytochromes. While <span class="Italics">in vivo </span>data to address this question are limited, results from drug interaction studies suggest that escitalopram, at a dose of 20 mg, has no 3A4 inhibitory effect and a modest 2D6 inhibitory effect. See <span class="Italics"><a href="#Section_7.20">Drug Interactions (7.18)</a></span>for more detailed information on available drug interaction data.</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis &amp; Mutagenesis &amp; Impairment Of Fertility</h2>
<br>         Carcinogenesis <br>         Racemic citalopram was administered in the diet to NMRI/BOM <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> mice and COBS WI <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> rats for 18 and 24 months, respectively. There was no evidence for carcinogenicity of racemic citalopram in mice receiving up to 240 mg/kg/day. There was an increased incidence of small intestine carcinoma in rats receiving 8 or 24 mg/kg/day racemic citalopram. A no-effect dose for this finding was not established. The relevance of these findings to humans is unknown. <br>         <br>         Mutagenesis <br>         Racemic citalopram was mutagenic in the in vitro bacterial reverse mutation assay (Ames test) in 2 of 5 bacterial <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> (<span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> TA98 and TA1537) in the absence of metabolic activation. It was clastogenic in the <span class="Italics">in vitro</span> Chinese hamster lung cell assay for chromosomal aberrations in the presence and absence of metabolic activation. Racemic citalopram was not mutagenic in the <span class="Italics">in vitro</span> mammalian forward gene mutation assay (HPRT) in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells or in a coupled <span class="Italics">in vitro/in vivo </span>unscheduled DNA synthesis (UDS) assay in rat liver. It was not clastogenic in the <span class="Italics">in vitro</span> chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or in two in vivo mouse micronucleus assays. <br>        <br>         Impairment of Fertility <br>         When racemic citalopram was administered orally to 16 male and 24 female rats prior to and throughout mating and gestation at doses of 32, 48, and 72 mg/kg/day, mating was decreased at all doses, and fertility was decreased at doses ≥ 32 mg/kg/day. Gestation duration was increased at 48 mg/kg/day.</div>
<div class="Section" data-sectionCode="34091-9">
<a name="Section_13.2"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Pharmacology &amp; OR Toxicology</h2>
<br>      Retinal Changes in Rats<br>      Pathologic changes (degeneration/<span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>) were observed in the retinas of albino rats in the 2-year carcinogenicity study with racemic citalopram. There was an increase in both incidence and severity of retinal pathology in both male and female rats receiving 80 mg/kg/day. Similar findings were not present in rats receiving 24 mg/kg/day of racemic citalopram for two years, in mice receiving up to 240 mg/kg/day of racemic citalopram for 18 months, or in dogs receiving up to 20 mg/kg/day of racemic citalopram for one year.<br><br>      Additional studies to investigate the mechanism for this pathology have not been performed, and the potential significance of this effect in humans has not been established.<br><br>      Cardiovascular Changes in Dogs <br>      In a one-year toxicology study, 5 of 10 beagle dogs receiving oral racemic citalopram doses of 8 mg/kg/day died suddenly between weeks 17 and 31 following initiation of treatment. <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden deaths</span> were not observed in rats at doses of racemic citalopram up to 120 mg/kg/day, which produced plasma levels of citalopram and its metabolites demethylcitalopram and didemethylcitalopram (DDCT) similar to those observed in dogs at 8 mg/kg/day. A subsequent intravenous dosing study demonstrated that in beagle dogs, racemic DDCT caused QT prolongation, a known risk factor for the observed outcome in dogs.</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<br><span class="Bold">Adolescents <br></span>         The efficacy of escitalopram oxalate as an acute treatment for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> in adolescent patients was established in an 8-week, flexible-dose, placebo-controlled study that compared escitalopram oxalate 10 to 20 mg/day to placebo in outpatients 12 to 17 years of age inclusive who met DSM-IV criteria for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>. The primary outcome was change from baseline to endpoint in the Children’s <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale - Revised (CDRS-R). In this study, escitalopram oxalate showed statistically significant greater mean improvement compared to placebo on the CDRS-R.<br> <br>         The efficacy of escitalopram oxalate in the acute treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> in adolescents was established, in part, on the basis of extrapolation from the 8-week, flexible-dose, placebo-controlled study with racemic citalopram 20 to 40 mg/day. In this outpatient study in children and adolescents 7 to 17 years of age who met DSM-IV criteria for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>, citalopram treatment showed statistically significant greater mean improvement from baseline, compared to placebo, on the CDRS-R; the positive results for this trial largely came from the adolescent subgroup.<br> <br>          Two additional flexible-dose, placebo-controlled MDD studies (one escitalopram oxalate study in patients ages 7 to 17 and one citalopram study in adolescents) did not demonstrate efficacy.<br><br>         Although maintenance efficacy in adolescent patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of escitalopram pharmacokinetic parameters in adults and adolescent patients.<br> <br><span class="Bold">Adults <br></span>         The efficacy of escitalopram oxalate as a treatment for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> was established in three, 8-week, placebo-controlled studies conducted in outpatients between 18 and 65 years of age who met DSM-IV criteria for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>. The primary outcome in all three studies was change from baseline to endpoint in the Montgomery Asberg <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale (MADRS). <br><br>         A fixed-dose study compared 10 mg/day escitalopram oxalate and 20 mg/day escitalopram oxalate to placebo and 40 mg/day citalopram. The 10 mg/day and 20 mg/day escitalopram oxalate treatment groups showed statistically significant greater mean improvement compared to placebo on the MADRS. The 10 mg and 20 mg escitalopram oxalate groups were similar on this outcome measure.<br> <br>         In a second fixed-dose study of 10 mg/day escitalopram oxalate and placebo, the 10 mg/day escitalopram oxalate treatment group showed statistically significant greater mean improvement compared to placebo on the MADRS.<br> <br>         In a flexible-dose study, comparing escitalopram oxalate, titrated between 10 and 20 mg/day, to placebo and citalopram, titrated between 20 and 40 mg/day, the escitalopram oxalate treatment group showed statistically significant greater mean improvement compared to placebo on the MADRS.<br> <br>         Analyses of the relationship between treatment outcome and age, gender, and race did not suggest any differential responsiveness on the basis of these patient characteristics.<br> <br>         In a longer-term trial, 274 patients meeting (DSM-IV) criteria for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>, who had responded during an initial 8-week, open-label treatment phase with escitalopram oxalate 10 or 20 mg/day, were randomized to continuation of escitalopram oxalate at their same dose, or to placebo, for up to 36 weeks of observation for relapse. Response during the open-label phase was defined by having a decrease of the MADRS total score to ≤ 12. Relapse during the double-blind phase was defined as an increase of the MADRS total score to ≥ 22, or discontinuation due to insufficient clinical response. Patients receiving continued escitalopram oxalate experienced a statistically significant longer time to relapse compared to those receiving placebo.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-14.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></h2>
<br>         The efficacy of escitalopram oxalate in the acute treatment of <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span> (GAD) was demonstrated in three, 8-week, multicenter, flexible-dose, placebo-controlled studies that compared escitalopram oxalate 10 to 20 mg/day to placebo in adult outpatients between 18 and 80 years of age who met DSM-IV criteria for GAD. In all three studies, escitalopram oxalate showed statistically significant greater mean improvement compared to placebo on the Hamilton <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> Scale (HAM-A).<br> <br>         There were too few patients in differing ethnic and age groups to adequately assess whether or not escitalopram oxalate has differential effects in these groups. There was no difference in response to escitalopram oxalate between men and women.</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_16.1"></a><a name="section-15.1"></a><p></p>
<h2>16.2 Oral Solution</h2>
<br>5 mg/5 mL, peppermint flavor (240 mL) NDC 31722-569-24<br><br><span class="Bold">Store at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature].</span>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<br>See FDA-approved Medication Guide<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Information for Patients</h2>
<br>Physicians are advised to discuss the following issues with patients for whom they prescribe escitalopram oxalate<br><br><span class="Bold">General Information about Medication Guide <br></span>Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with escitalopram oxalate and should counsel them in its appropriate use. A patient Medication Guide about “Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other Serious Mental Illness, and Suicidal Thoughts or Actions? is available for escitalopram oxalate. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document. <br><br>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking escitalopram oxalate. <br><br><span class="Bold">Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk <br></span>Patients, their families, and their caregivers should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, other unusual changes in behavior, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication [<span class="Italics">see <a href="#Section_5.1">Warnings and Precautions (5.1)</a></span>].<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> <br></span>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the concomitant use of escitalopram oxalate and triptans, tramadol or other serotonergic agents [<span class="Italics">see <a href="#Section_5.2">Warnings and Precautions (5.2</a>)</span>]. <br><br><span class="Bold">Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> <br></span>Patients should be cautioned about the concomitant use of escitalopram oxalate and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> [<span class="Italics">see <a href="#Section_5.8">Warnings and Precautions (5.7)</a></span>]. <br><br><span class="Bold">Concomitant Medications <br></span>Since escitalopram is the active isomer of racemic citalopram, the two agents should not be coadministered. Patients should be advised to inform their physician if they are taking, or plan to take, any prescription or over-the-counter drugs, as there is a potential for interactions.<br> <br><span class="Bold">Continuing the Therapy Prescribed <br></span>While patients may notice improvement with escitalopram oxalate therapy in 1 to 4 weeks, they should be advised to continue therapy as directed. <br><br><span class="Bold">Interference with Psychomotor Performance<br></span>Because psychoactive drugs may impair judgment, thinking, or motor skills, patients  should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that escitalopram oxalate therapy does not affect their ability to engage in such activities.<br> <br><span class="Bold">Alcohol <br></span>Patients should be told that, although escitalopram oxalate has not been shown in experiments with normal subjects to increase the mental and motor skill impairments caused by alcohol, the concomitant use of escitalopram oxalate and alcohol in depressed patients is not advised.<br> <br><span class="Bold">Pregnancy and Breast Feeding <br></span>Patients should be advised to notify their physician if they              <br>            Ø become pregnant or intend to become pregnant during therapy. <br>   Ø are breastfeeding an infant.       <br><br><span class="Bold">Need for Comprehensive Treatment Program<br></span>Escitalopram oxalate is indicated as an integral part of a total treatment program for MDD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all adolescents with this syndrome. Safety and effectiveness of escitalopram oxalate in MDD has not been established in pediatrics patients less than 12 years of age. Antidepressants are not intended for use in the adolescent who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe antidepressant medication will depend upon the physician’s assessment of the chronicity and severity of the patient’s symptoms.</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.2"></a><a name="section-16.2"></a><p></p>
<h2>17.2 FDA-Approved Medication Guide</h2>
<br><span class="Bold">Escitalopram Oxalate Oral Solution</span>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="Unclassified_Section_54"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<br>Read the Medication Guide that comes with escitalopram oxalate oral solution before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk with your healthcare provider if there is something you do not understand or want to learn more about.<br><br><span class="Bold">What is the most important information I should know about escitalopram oxalate oral solution? <br></span><br>Escitalopram oxalate oral solution and other antidepressant medicines may cause serious side effects, including:<br> <br><span class="Bold">1. Suicidal thoughts or actions: <br></span>   • E<span class="Bold">scitalopram oxalate oral solution and other antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment or when the dose is changed. <br></span>   • <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> or other serious mental illnesses are the most important causes of suicidal thoughts or actions. <br>   • Watch for these changes and call your healthcare provider right away if you notice: <br>            • New or sudden changes in mood, behavior, actions, thoughts, or feelings, especially if severe. <br>            • Pay particular attention to such changes when escitalopram oxalate oral solution is started or when the dose is changed. <br><br>Keep all follow-up visits with your healthcare provider and call between visits if you are worried about symptoms.<br> <br><span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you: <br></span>         • attempts to commit suicide <br>         • acting on dangerous impulses <br>         • acting aggressive or violent <br>         • thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying <br>         • new or worse depression <br>         • new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or panic attacks <br>         • feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span>, angry or irritable <br>         • trouble sleeping <br>         • an increase in activity or talking more than what is normal for you<br>         • other unusual changes in behavior or mod<br> <br><span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency. Escitalopram oxalate oral solution may be associated with these serious side effects:<br><br></span><br><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>-like reactions. This condition can be life-threatening and may include: <br></span>         • <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or other changes in mental status <br>         • coordination problems or <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span> (overactive reflexes) <br>         • racing heartbeat, high or low blood pressure <br>         • <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or fever <br>         • <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or diarrhea <br>         • <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> <br><br><span class="Bold">3. Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>: <br></span>         • trouble breathing <br>         • <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, tongue, eyes or mouth <br>         • <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">welts</span> (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>) or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, alone or with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span><br> <br><span class="Bold">4. Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span> Escitalopram oxalate oral solution and other antidepressant medicines may increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, especially if you take the blood thinner warfarin (Coumadin®, Jantoven®), a non-steroidal anti-inflammatory drug (NSAIDs, like ibuprofen or naproxen), or aspirin. <br><br><span class="Bold">5. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> <br></span><br><span class="Bold">6. <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic episodes</span>:</span> <br>         • greatly increased energy <br>         • severe trouble sleeping <br>         • racing thoughts <br>         • reckless behavior <br>         • unusually grand ideas <br>         • excessive happiness or irritability <br>         • talking more or faster than usual <br><br><span class="Bold">7. Changes in appetite or weight.</span> Children and adolescents should have height and weight monitored during treatment.<br> <br><span class="Bold">8. Low salt (sodium) levels in the blood. Elderly people may be at greater risk for this. Symptoms may include:<br></span>         • headache <br>         • <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or feeling unsteady <br>         • <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, problems concentrating or thinking or memory problems<br><br><span class="Bold">Do not stop escitalopram oxalate oral solution without first talking to your healthcare provider. Stopping escitalopram oxalate oral solution too quickly may cause serious symptoms including: <br></span>         • <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, high or low mood, feeling <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span> or changes in sleep habits <br>         • <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, dizziness <br>         • <span class="product-label-link" type="condition" conceptid="439396" conceptname="Injury due to electrical exposure">electric shock</span>-like sensations, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span><br> <br><span class="Bold">What is escitalopram oxalate oral solution? <br></span>Escitalopram oxalate oral solution is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It is important to talk with your healthcare provider about the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risks of not treating it. You should discuss all treatment choices with your healthcare provider. Escitalopram oxalate oral solution is also used to treat: <br>         • Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD) <br>         • <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span> (GAD)<br><br>Talk to your healthcare provider if you do not think that your condition is getting better with escitalopram oxalate oral solution treatment.<br><span class="Bold"><br>Who should not take escitalopram oxalate oral solution? <br></span>Do not take escitalopram oxalate oral solution if you: <br>• are allergic to escitalopram oxalate or citalopram hydrobromide or any of the ingredients in escitalopram oxalate oral solution. See the end of this Medication Guide for a complete list of ingredients in escitalopram oxalate oral solution. <br>• take a Monoamine Oxidase Inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid. <br>         • Do not take an MAOI within 14 days of stopping escitalopram oxalate oral solution. <br>         • Do not start escitalopram oxalate oral solution if you stopped taking an MAOI in the last 14 days. <br><br><span class="Bold">People who take escitalopram oxalate oral solution close in time to an MAOI may have serious or even life-threatening side effects. Get medical help right away if you have any of these symptoms:</span><br>         • high fever <br>         • uncontrolled <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span><br>         • stiff muscles <br>         • rapid changes in heart rate or blood pressure <br>         • confusion <br>         • <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> (pass out) <br><br> • <span class="Bold">take the antipsychotic medicine pimozide (Orap<span class="Sup">®</span>) because taking this drug with escitalopram oxalate oral solution can cause serious heart problems.</span><br><br><span class="Bold">What should I tell my healthcare provider before taking escitalopram oxalate oral solution? Ask if you are not sure.<br><br></span>Before starting escitalopram oxalate oral solution, tell your healthcare provider if you: <br>          • Are taking certain drugs such as: <br>               • Triptans used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> headache <br>               • Medicines used to treat mood, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> or thought disorders, including tricyclics, lithium, SSRIs, SNRIs, or antipsychotics <br>               • tramadol <br>               • Over-the-counter supplements such as tryptophan or St. John’s Wort <br>               • have liver problems <br>               • have kidney problems <br>               • have heart problems <br>               • have or had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or convulsions <br>               • have bipolar disorder or mania <br>               • have low sodium levels in your blood <br>               • have a history of a stroke <br>               • have high blood pressure <br>               • have or had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems <br>               • are pregnant or plan to become pregnant. It is not known if escitalopram oxalate oral solution will harm your unborn baby. Talk to your healthcare provider about the benefits and risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> during pregnancy <br>               • are breast-feeding or plan to breast-feed. Some escitalopram oxalate oral solution may pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking escitalopram oxalate oral solution.<br> <br><span class="Bold">Tell your healthcare provider about all the</span> medicines <span class="Bold">that you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. Escitalopram oxalate oral solution and some medicines may interact with each other, may not work as well, or may cause serious side effects. <br><br> <br>Your healthcare provider or pharmacist can tell you if it is safe to take escitalopram oxalate oral solution with your other medicines. Do not start or stop any medicine while taking escitalopram oxalate oral solution without talking to your healthcare provider first.<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule" align="justify" valign="top">
<br> If you take escitalopram oxalate oral solution, you should not take any other medicines that contain escitalopram oxalate or citalopram hydrobromide including: Citalopram.</td></tr></tbody></table>
<br> <br><span class="Bold">How should I take escitalopram oxalate oral solution? <br></span>            • Take escitalopram oxalate oral solution exactly as prescribed. Your healthcare provider may need to change the dose of escitalopram oxalate oral solution until it is the right dose for you. <br>            • Escitalopram oxalate oral solution may be taken with or without food. <br>            • If you miss a dose of escitalopram oxalate oral solution, take the missed dose as soon as you remember. If it is almost time for the next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses of escitalopram oxalate oral solution at the same time. <br>            • If you take too much escitalopram oxalate oral solution, call your healthcare provider or poison control center right away, or get emergency treatment.<br> <br><span class="Bold">What should I avoid while taking escitalopram oxalate oral solution?</span><br> Escitalopram oxalate oral solution can cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or may affect your ability to make decisions, think clearly, or react quickly. You should not drive, operate heavy machinery, or do other dangerous activities until you know how escitalopram oxalate oral solution affects you. Do not drink alcohol while using escitalopram oxalate oral solution.<br> <br><span class="Bold">What are the possible side effects of escitalopram oxalate oral solution? <br></span>Escitalopram oxalate oral solution may cause serious side effects, including all of those described in the section entitled “What is the most important information I should know about escitalopram oxalate oral solution??<br> <br>Common possible side effects in people who take escitalopram oxalate oral solution include: <br>         • Nausea <br>         • Sleepiness <br>         • Weakness <br>         • Dizziness <br>         • Feeling anxious <br>         • Trouble sleeping <br>         • Sexual problems <br>         • Sweating <br>         • Shaking <br>         • Not feeling hungry <br>         • Dry mouth <br>         • Constipation <br>         • Infection <br>         • <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">Yawning</span> <br><br>Other side effects in children and adolescents include: <br>          • increased thirst <br>          • abnormal increase in muscle movement or agitation <br>          • nose bleed <br>          • difficult urination <br>          • heavy menstrual periods <br>          • possible slowed growth rate and weight change<br> <br>         Your child’s height and weight should be monitored during treatment with escitalopram oxalate oral solution. <br><br>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of escitalopram oxalate oral solution. For more information, ask your healthcare provider or pharmacist.<br> <br><span class="Bold">CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1-800-FDA-1088.</span><br> <br><span class="Bold">How should I store escitalopram oxalate oral solution? <br></span>         • Store escitalopram oxalate oral solution at 20 to 25°C (68 to 77°F). [see USP Controlled Room Temperature]<br>         • Keep escitalopram oxalate oral solution bottle closed tightly. <br><span class="Bold"><br>Keep escitalopram oxalate oral solution and all medicines out of the reach of children. <br><br>General information about escitalopram oxalate oral solution<br></span>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use escitalopram oxalate oral solution for a condition for which it was not prescribed. Do not give escitalopram oxalate oral solution to other people, even if they have the same condition. It may harm them. <br><br>This Medication Guide summarizes the most important information about escitalopram oxalate oral solution. If you would like more information, talk with your healthcare provider. You may ask your healthcare provider or pharmacist for information about escitalopram oxalate oral solution that is written for healthcare professionals.<br> <br><span class="Bold">What are the ingredients in escitalopram oxalate oral solution? <br></span>Active ingredient: escitalopram oxalate<br><br>Inactive ingredients:  anhydrous citric acid, glycerin, malic acid, methylparaben, natural peppermint flavor, non-crystallizing sorbital solution, propylene glycol, propylparaben, purified water and sodium citrate dihydrate.<br><br>Manufactured for:                         2014779<br>Camber Pharmaceuticals, Inc.  <br>Piscataway, NJ 08854<br><br>By: Hetero Labs Limited<br>Jeedimetla, Hyderabad – 500 055, India.  <br>                                         <br>Revised 10/2011<br><br>Coumadin<span class="Sup">®</span>, Jantoven<span class="Sup">®</span> and Orap<span class="Sup">®</span> are the registered trademarks of their respective owners and are not the trademarks of Hetero Labs Limited.<br> <br>This Medication Guide has been approved by the U.S. Food and Drug Administration.</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_19"></a><a name="section-18"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<br>Escitalopram Oxalate Oral Solution 5 mg/5 mL - 240 mL Container Label<br><div class="Figure"><img alt="240mLcontainer.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=82d793ee-4039-45fc-ac83-4bd5235f00aa&amp;name=240mLcontainer.jpg"></div> </div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ESCITALOPRAM OXALATE  		
					</strong><br><span class="contentTableReg">escitalopram oxalate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:31722-569</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESCITALOPRAM OXALATE</strong> (ESCITALOPRAM) </td>
<td class="formItem">ESCITALOPRAM</td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEPPERMINT</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">PEPPERMINT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:31722-569-24</td>
<td class="formItem">240 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202221</td>
<td class="formItem">06/12/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Camber Pharmaceuticals, Inc.
							(826774775)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Hetero Labs Limited (676162024)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hetero Labs Limited</td>
<td class="formItem"></td>
<td class="formItem">676162024</td>
<td class="formItem">ANALYSIS(31722-569), MANUFACTURE(31722-569)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>82d793ee-4039-45fc-ac83-4bd5235f00aa</div>
<div>Set id: 82d793ee-4039-45fc-ac83-4bd5235f00aa</div>
<div>Version: 1</div>
<div>Effective Time: 20111001</div>
</div>
</div> <div class="DistributorName">Camber Pharmaceuticals, Inc.</div></p>
</body></html>
